Quick Answer
Arcus Biosciences, Inc. reported Cash and Equivalents of $222.00 million for fiscal year 2025.
Arcus Biosciences, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $222.00M | +48.0% |
| 2024 | $150.00M | +18.1% |
| 2023 | $127.00M | -38.3% |
| 2022 | $206.00M | +39.2% |
| 2021 | $148.00M | -14.7% |
| 2020 | $173.41M | +199.3% |
| 2019 | $57.94M | -18.5% |
| 2018 | $71.06M | -27.8% |
| 2017 | $98.43M | +51.1% |
| 2016 | $65.16M | +39.0% |
| 2015 | $46.87M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $238.00M | +18.4% | -4.0% |
| June 30, 2025 | $248.00M | +59.0% | +29.2% |
| March 31, 2025 | $192.00M | +3.8% | +28.0% |
| December 31, 2024 | $150.00M | +18.1% | -25.4% |
| September 30, 2024 | $201.00M | +9.2% | +28.8% |
| June 30, 2024 | $156.00M | -32.2% | -15.7% |
| March 31, 2024 | $185.00M | -22.3% | +45.7% |
| December 31, 2023 | $127.00M | -38.3% | -31.0% |
- Arcus Biosciences, Inc. showed an increase of +48.0% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2015–2025 period, Arcus Biosciences, Inc.’s cash and equivalents has grown by 373.7% (from $46.87 million to $222.00 million).
- The most recent figure is from Arcus Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: